Black Diamond Therapeutics, Inc. (BDTX)

The chart shows the growth of $10,000 invested in Black Diamond Therapeutics, Inc. in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $413 for a total return of roughly -95.87%. All prices are adjusted for splits and dividends.

Black Diamond Therapeutics, Inc. had a return of -9.44% year-to-date (YTD) and -44.37% in the last 12 months. Over the past 10 years, Black Diamond Therapeutics, Inc. had an annualized return of -63.91%, while the S&P 500 had an annualized return of 5.80%, indicating that Black Diamond Therapeutics, Inc. did not perform as well as the benchmark.

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Black Diamond Therapeutics, Inc. Sharpe ratio is -0.55. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

The Drawdowns chart displays portfolio losses from any high point along the way.

The table below shows the maximum drawdowns of the Black Diamond Therapeutics, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Black Diamond Therapeutics, Inc. is 97.17%, recorded on Oct 13, 2022. The portfolio has not recovered from it yet.

Current Black Diamond Therapeutics, Inc. volatility is 141.80%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.